EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer—a monocentric experience

Manuel Weber iD, Leah Trumet, Fabienne Lange, Julia Murk, Philipp Schubert, Hasan Alsamra, Joy Backhaus, Stefanie Corradini, Marco Kesting, Sarina Müller, Joan Morris, Marlen Haderlein

Cancer Immunology, Immunotherapy · 04.09.2026 · 75 (10)

DOI: 10.1007/s00262-026-04515-8 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 04.09.2026. Verfasst von Manuel Weber und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Cranio-Maxillofacial Surgery, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054, Erlangen, …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy, Mouth Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Erlangen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Combination immunotherapy has shown encouraging activity across multiple solid tumors. We report the complete and consecutive cohort of patients with locally advanced oral squamous cell carcinoma (OSCC) treated at a single center within the prospective, multicenter, randomized phase 2 BelieveIT-201 trial (ASND0038), evaluating neoadjuvant intratumoral Toll-like receptor (TLR) 7/8 agonist (TransCon TLR7/8 Agonist) therapy combined with systemic immunotherapy.

Methods

Patients with non-metastatic OSCC treated within the BelieveIT-201 trial (ASND0038) between April and December 2024 were included. Neoadjuvant therapy comprised two cycles of intratumoral TransCon TLR7/8 Agonist combined with either intravenous pembrolizumab or TransCon IL-2 β/γ according to 1:1 randomization, followed by surgical resection. The trial was terminated prematurely by the sponsor for reasons unrelated to safety or efficacy, which limited the cohort to six patients. Clinical, radiographic, pathological responses, and safety were assessed. Immunohistochemical analyses of paired pre- and post-treatment tumor samples evaluated immune cell infiltration (CD3, CD8, CD68, CD163). The individual patient was the unit of analysis, and given the small number of patients all analyses are descriptive; no inferential statistical testing was performed. Progression-free survival (PFS) and overall survival (OS) are reported as absolute event counts.

Results

Six patients were treated (median age 63 years; median follow-up 81 weeks). Three patients achieved a major clinical response, two showed partial response, and one had progressive disease. Pathologic evaluation revealed one complete response, one major response, and four non-responses. All patients underwent surgery; postoperative morbidity was substantial, with at least one grade III adverse event in every patient and one postoperative death. All three patients with a major clinical response developed sterile tumor-associated pseudoabscesses in spatial proximity to the injection site. Immunohistochemical analyses revealed remodeling of the tumor immune microenvironment, including increased T-cell infiltration, most pronounced in the tumor center. Within the first year, two of six patients experienced a progression-free survival event ( n = 1 progressive disease, n = 1 death). After surgery none of the patients showed disease recurrence.

Conclusion

Neoadjuvant intratumoral TransCon TLR7/8 Agonist-based combination immunotherapy was feasible in this small prospective cohort of patients with locally advanced OSCC and was accompanied by consistent remodeling of the tumor immune microenvironment. Because of the limited number of patients and the premature termination of the parent trial, no conclusions on efficacy or on comparative tolerability can be drawn.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyMouth NeoplasmsNeoadjuvant TherapyToll-Like Receptor AgonistsAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesToll-Like Receptor 7Toll-Like Receptor 8

Stichwörter der Autor:innen

HNSCCLocal immune activationOSCCOral cancer

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabTLR7 protein, humanTLR8 protein, humanToll-Like Receptor 7Toll-Like Receptor 8Toll-Like Receptor Agonists

Autor:innen und Institutionen

  • Department of Oral and Cranio-Maxillofacial Surgery, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany. manuel.weber@uk-erlangen.de.
  • Deutsches Zentrum Immuntherapie (DZI) and Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. manuel.weber@uk-erlangen.de.
  • Department of Operative Dentistry and Periodontology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg (FAU), Erlangen, Germany.
  • Department of Oral and Cranio-Maxillofacial Surgery, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.

ORCID-Profile: Manuel Weber

Förderung

  • Universitätsklinikum Erlangen

Zitieren

APA

Weber, M., Trumet, L., Lange, F., Murk, J., Schubert, P., Alsamra, H., Backhaus, J., Corradini, S., Kesting, M., Müller, S., Morris, J., & Haderlein, M. (2026). Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer—a monocentric experience. Cancer Immunology, Immunotherapy, 75(10). https://doi.org/10.1007/s00262-026-04515-8

Vancouver

Weber M, Trumet L, Lange F, Murk J, Schubert P, Alsamra H, et al. Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer—a monocentric experience. Cancer Immunology, Immunotherapy. 2026;75(10). doi:10.1007/s00262-026-04515-8

BibTeX
@article{Weber2026,
  author = {Weber, Manuel and Trumet, Leah and Lange, Fabienne and Murk, Julia and Schubert, Philipp and Alsamra, Hasan and Backhaus, Joy and Corradini, Stefanie and Kesting, Marco and Müller, Sarina and Morris, Joan and Haderlein, Marlen},
  title = {Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer—a monocentric experience},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {10},
  doi = {10.1007/s00262-026-04515-8}
}
Kostenlos starten →